After we con- trolled the familywise error rate for the three key secondary outcomes, the rate of first and subse- quent hospitalizations from any cause was lower in the empagliflozin group than in the placebo group (24.8 vs. 29.2 hospitalizations per 100 patient-years; hazard ratio, 0.86; 95% CI, 0.78 to 0.95; P = 0.003) (Table 2 and Table S4).